SCHEMBL9719360

SCHEMBL9719360

CC(=O)c1ccc2c(c1)C(Cc1ccncc1)c1ccccc1-2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HTR7 P34969 2/20 0.38
HTR2B P41595 2/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
PKM P14618 2/20 0.38
RECQL P46063 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B1 P14061 1/20 0.37
CYP19A1 P11511 1/20 0.36
LMNA P02545 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PDK2 Q15119 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8111113 0.80 CYP19A1 (0.47) MAPTNPC1RAB9ACYP19A1SMN1; SMN2
Hydrochloric Acid SCHEMBL9719344 0.79 CYP19A1 (0.46) MAPTNPC1RAB9ACYP19A1SMN1; SMN2
SCHEMBL9269160 0.73 CYP19A1 (0.41) CYP19A1
SCHEMBL9266327 0.73 CYP19A1 (0.41) CYP19A1
SCHEMBL17500281 0.71 RXRA (0.49) MAPTALDH1A1PKM
SCHEMBL10965346 0.71 HTR7 (0.62) S100A4MAPTNPC1RAB9AHTR7
SCHEMBL9267697 0.70 KCNQ2 (0.57) S100A4MAPTNPC1RAB9AALDH1A1
SCHEMBL7983280 0.69 CYP19A1 (0.39) MAPTALDH1A1KDM4ERECQLMEN1
Hydrochloric Acid SCHEMBL9266879 0.69 KCNQ2 (0.56) S100A4MAPTNPC1RAB9AALDH1A1
SCHEMBL17022656 0.68 HTR2A (0.56) MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992000760-A1 METHOD OF TREATING NEUROLOGICAL DYSFUNCTION USING NEUROTRANSMITTER ENHANCES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-01-23 WO disclosed